K.A. Bizhanov

https://orcid.org/0000-0002-6668-7373

Articles found: 3

  • The role of interleukins in the pathogenesis of atrial fibrillation: literature review (Issue № 3, 2024)

    A.T. Aubakirova, A.K. Baimbetov, A.V. Sapunov, I.A. Yakupova, K.A. Bizhanov, L.E. Rizabekova, N.J. Bigeldiev
    2024-09-30
    90–97
    Abstract

    Relevance. Atrial fibrillation (AF) is the most common arrhythmia, which negatively affects the quality of life and significantly increases the risk of thrombosis, strokes and cardiovascular diseases. The pathogenesis of AF is a complex and multifactorial process in which inflammatory and immune mechanisms play an important role. In recent years, special attention has been paid to interleukins, cytokines that regulate the immune response, which may influence the development and maintenance of AF. The study of the role of interleukins in the pathogenesis of AF may provide new perspectives for understanding the mechanisms of the occurrence of this arrhythmia and the development of effective methods of its prevention and treatment. The study aimed to evaluate the influence of interleukins on the pathogenesis of atrial fibrillation and to identify possible mechanisms of their action.

    Methods. data concerning the role of interleukins in the pathogenesis of atrial fibrillation were analyzed during the analysis of scientific publications. A systematization of existing studies, including both clinical and experimental data that show a link between the levels of interleukins (IL-1, IL-6, IL-17 and others) and the development of AF was performed. Search methods included analyzing publications in PubMed, Scopus and Web of Science databases over the last ten years and using keywords related to interleukins and AF.

    Results. The results indicate that interleukins such as IL-1, IL-6, IL-17 and IL-18 play a significant role in the inflammatory processes associated with AF. Elevated levels of IL-6 correlate with worsening cardiac function and an increased likelihood of developing AF. In addition, IL-1 may contribute to myocardial remodeling, which is a key factor in the pathogenesis of AF. Other interleukins, such as IL-17, are also associated with inflammatory processes affecting cardiac electrical stability. Accumulating evidence suggests that interleukins can affect cellular hypertrophy and fibrosis, leading to changes in cardiac structure and contributing to the development of AF. The inclusion of interleukins in risk prediction models for the development of AF may improve preventive strategies and individualize the treatment of patients at risk.

    Conclusion. the analysis shows that interleukins play a key role in the pathogenesis of atrial fibrillation by participating in inflammatory processes and abnormalities in cardiac electrophysiology. Further studies are needed to clarify their mechanisms of action and to develop new therapeutic strategies aimed at reducing interleukin levels and improving the prognosis of patients with AF.

    Keywords

    atrial fibrillation, interleukins, inflammation, pathogenesis, cardiovascular diseases, IL-1, IL-6, IL-17

  • The influence of pulmonary vein anatomy on outcomes after ablation of paroxysmal atrial fibrillation (Issue № 3, 2024)

    A. Baimbetov, A. Jukenova, A. Ualiyeva, K. Bizhanov, A. Sapunov, N. Bigeldiyev, K. Yakupova, N. Okhabekov, Zh. Meirambay
    2024-09-30
    82–89
    Abstract

    Background. Pulmonary vein isolation is the cornerstone of catheter-based treatment for atrial fibrillation. Cryoballoon ablation offers an effective and reproducible method for pulmonary vein isolation, yet recurrence of arrhythmias remains a challenge. Despite advances in catheter technologies, the role of altered pulmonary vein anatomy as a factor for atrial fibrillation recurrence is poorly studied. Materials and

    Methods. This prospective study included 465 patients with paroxysmal atrial fibrillation who underwent cryoballoon ablation. Pulmonary vein and left atrial anatomy were evaluated using multislice computed tomography. Patients were followed for 24–48 months to assess atrial fibrillation recurrence and anatomical risk factors. Cox proportional hazard modeling and Kaplan-Meier analysis were used to evaluate predictors of arrhythmia recurrence.

    Results. Complete Pulmonary vein isolation was achieved in all patients. During follow-up, 38% of patients experienced atrial fibrillation recurrence. Patients with altered pulmonary vein anatomy, particularly a left common pulmonary vein and additional pulmonary veins, showed a higher rate of recurrence. Cox regression analysis identified left atrial volume index >50 mL/m² and pathological pulmonary vein anatomy as independent risk factors for atrial fibrillation recurrence.

    Conclusion. Altered pulmonary vein anatomy is a significant risk factor for atrial fibrillation recurrence following cryoballoon ablation. Comprehensive imaging of the left atrial and pulmonary vein using multislice computed tomography can improve patient selection, reducing the recurrence risk and improving long-term outcomes.

    Keywords

    Atrial fibrillation, cryoballoon ablation, pulmonary vein anatomy, recurrence, pulmonary vein isolation, multislice computed tomography

  • WHAT SCALES SHOULD THE CARDIOLOGIST USE IN PATIENTS WITH ATRIAL FIBRILLATION? WHAT IS NEW? (Issue № 2, 2024)

    K.A. Bizhanov, A.K. Baimbetov, B.B. Baimakhanov, Sh.A. Kaniev, O.T. Ibekenov, A.B. Sarsenbaeva, G.N. Ismailova
    2024-06-28
    61–77
    Abstract

    The current treatment algorithm for patients with non-valvular atrial fibrillation (AF) includes anticoagulation to prevent stroke and systemic embolism, improvement of AF symptom control by heart rate reduction or restoration and maintenance of sinus rhythm, and treatment of cardiovascular and other comorbidities. The evaluation of patients with AF should be structured and include assessment of stroke risk, symptom severity, severity of the AF burden (type of arrhythmia, number and duration of episodes, etc.) and predisposing condition. The use of the CHA2DS2-VASc (risk of stroke), HAS-BLED (risk of bleeding), EHRA (severity of AF symptoms), and 2MACE (risk of cardiovascular outcomes) scales is important to help assess the likelihood of adverse outcomes and select the optimal treatment to protect not only against stroke but also against cardiovascular events. It should be noted that the HAS-BLED scale is primarily necessary for identification of bleeding risk factors, the modification of which allows to increase the safety of anticoagulant therapy, and a high index value according to this scale can’t serve as a reason to refuse anticoagulation in a patient with AF. New scales of stroke and hemorrhagic complications risk assessment in patients with AF on the basis of clinical parameters and laboratory biomarkers have been proposed, but their possible advantages over the existing indices need to be confirmed in special studies.

    Keywords

    Atrial fibrillation, stroke, bleeding, scales, direct oral anyicoagulants, myocardial infarction, interventional arrhythmology, cardiology